Fibrosis, Liver Clinical Trial
Official title:
Non-invasive Screening for Chronic Liver Diseases in the General Population. A Prospective Study
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
The prevalence of chronic liver diseases continues to increase on the one hand by the increase in non-alcoholic fatty liver disease (NAFLD) which affects 25% of the general population as well as the increased incidence of hepatocellular carcinoma in recent years. Screening for liver fibrosis in the general population represents a major public health issue. The FIB-4 score is obtained by a blood test. This score combines age, measurement of ALT/ASAT (alanine aminotransferase / aspartate-aminotransferase) and platelet count. This score is sensitive for detecting advanced fibrosis liver and allows 71% of patients to avoid a liver biopsy. Transient elastometry (Fibroscan®) is another very effective non-invasive assessment in the diagnosis of chronic liver diseases and hepatic fibrosis. It has already been demonstrated by several studies that combining several non-invasive fibrosis tests allows to improve the precision of the result. The investigators hypothesize that offering an additional assessment by Fibroscan for patients screened by a blood test (FIB-4 Score) as possibly having advanced liver fibrosis (Score >2.67) will raise awareness among professional practitioners and the general population with chronic liver diseases and refine screening for chronic liver diseases. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
| Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
| Active, not recruiting |
NCT05473806 -
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
|
Phase 4 | |
| Not yet recruiting |
NCT06463223 -
HIBOC = Hepatic Imaging Biomarkers in Obese Children
|
||
| Not yet recruiting |
NCT03222167 -
Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
|
Phase 3 | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Not yet recruiting |
NCT05567614 -
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
|
||
| Active, not recruiting |
NCT05402371 -
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
|
Phase 2 | |
| Completed |
NCT03373396 -
Impact of Chlordecone on Active Chronic Hepatitis
|
N/A | |
| Recruiting |
NCT02569567 -
Comparison of Smart-Shear Wave Elastography and Transient Elastography
|
N/A | |
| Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
| Completed |
NCT04493346 -
Shear Wave Elastography
|
||
| Completed |
NCT04380493 -
The Use of the Transient Elastography Paediatric Probe, Compared to the M Probe, Indirect Biomarkers and Histology
|
||
| Active, not recruiting |
NCT06315361 -
DIAbetes and NAFLD
|
||
| Not yet recruiting |
NCT03492879 -
Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity
|
N/A | |
| Recruiting |
NCT04442334 -
The European NAFLD Registry
|
||
| Recruiting |
NCT05692024 -
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
|
Phase 1/Phase 2 | |
| Completed |
NCT03659058 -
Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
|
N/A | |
| Recruiting |
NCT05218538 -
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
|
||
| Recruiting |
NCT06248580 -
Find HDV and Determine Its Status in Turkey
|